JP2010534220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534220A5 JP2010534220A5 JP2010517393A JP2010517393A JP2010534220A5 JP 2010534220 A5 JP2010534220 A5 JP 2010534220A5 JP 2010517393 A JP2010517393 A JP 2010517393A JP 2010517393 A JP2010517393 A JP 2010517393A JP 2010534220 A5 JP2010534220 A5 JP 2010534220A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- weight
- composition according
- silicon dioxide
- lercanidipine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 9
- 239000011230 binding agent Substances 0.000 claims 6
- 229960004294 lercanidipine Drugs 0.000 claims 6
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims 6
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 claims 5
- 229960002162 lercanidipine hydrochloride Drugs 0.000 claims 5
- 235000019359 magnesium stearate Nutrition 0.000 claims 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- 239000007909 solid dosage form Substances 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims 4
- 239000008109 sodium starch glycolate Substances 0.000 claims 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 229960001021 lactose monohydrate Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- -1 polyoxyethylene Polymers 0.000 claims 3
- 239000000080 wetting agent Substances 0.000 claims 3
- 229910002012 Aerosil® Inorganic materials 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 150000004682 monohydrates Chemical group 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2007/006517 WO2009012791A1 (en) | 2007-07-23 | 2007-07-23 | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
| PCT/EP2008/059645 WO2009013306A1 (en) | 2007-07-23 | 2008-07-23 | Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534220A JP2010534220A (ja) | 2010-11-04 |
| JP2010534220A5 true JP2010534220A5 (OSRAM) | 2011-09-15 |
Family
ID=39223083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517273A Expired - Fee Related JP5769963B2 (ja) | 2007-07-23 | 2007-07-23 | ジヒドロピリジンカルシウムチャンネルアンタゴニストを含む薬学的組成物とその調製方法 |
| JP2010517393A Pending JP2010534220A (ja) | 2007-07-23 | 2008-07-23 | ジヒドロピリジンカルシウムチャネル拮抗薬を含有する改善された医薬組成物およびその調製方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517273A Expired - Fee Related JP5769963B2 (ja) | 2007-07-23 | 2007-07-23 | ジヒドロピリジンカルシウムチャンネルアンタゴニストを含む薬学的組成物とその調製方法 |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP2180883B1 (OSRAM) |
| JP (2) | JP5769963B2 (OSRAM) |
| KR (2) | KR101632079B1 (OSRAM) |
| CN (3) | CN101784260A (OSRAM) |
| AU (2) | AU2007356942B2 (OSRAM) |
| BR (2) | BRPI0721883A2 (OSRAM) |
| CA (2) | CA2691752C (OSRAM) |
| CO (1) | CO6290639A2 (OSRAM) |
| CR (1) | CR11285A (OSRAM) |
| EA (2) | EA021645B1 (OSRAM) |
| EC (1) | ECSP109984A (OSRAM) |
| ES (2) | ES2622495T3 (OSRAM) |
| MA (1) | MA31684B1 (OSRAM) |
| MX (2) | MX2010000856A (OSRAM) |
| MY (1) | MY153857A (OSRAM) |
| NZ (2) | NZ582648A (OSRAM) |
| TN (2) | TN2010000011A1 (OSRAM) |
| UA (2) | UA97161C2 (OSRAM) |
| WO (2) | WO2009012791A1 (OSRAM) |
| ZA (2) | ZA201000586B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2009012791A1 (en) * | 2007-07-23 | 2009-01-29 | Pharmathen S.A. | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
| AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| MX2012005284A (es) | 2009-11-06 | 2012-06-28 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello. |
| KR101911972B1 (ko) | 2011-02-07 | 2018-10-25 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| GR1008554B (el) * | 2014-06-12 | 2015-09-03 | ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου |
| CN104069500A (zh) * | 2014-06-20 | 2014-10-01 | 湖南天地恒一制药有限公司 | 一种包含乐卡地平的药物组合物 |
| CN105168165B (zh) * | 2015-08-28 | 2018-06-26 | 江苏福邦药业有限公司 | 一种盐酸乐卡地平片及其制备方法 |
| WO2018004379A1 (ru) * | 2016-07-01 | 2018-01-04 | Общество С Ограниченной Ответственностью "Гиостин" | Средство в виде капсулы для лечения заболеваний суставов |
| MA52088A (fr) | 2018-03-22 | 2021-01-27 | Komipharm Int Australia Pty Ltd | Composition pharmaceutique comprenant du méta-arsénite et procédé de fabrication |
| CN114533686B (zh) * | 2022-02-15 | 2023-10-20 | 湖南普道医药技术有限公司 | 一种二氢吡啶类药物的口服固体制剂及其制备方法 |
| KR20240040407A (ko) * | 2022-09-21 | 2024-03-28 | 주식회사 종근당 | 사쿠비트릴ㆍ발사르탄 칼슘염을 포함하는 약제학적 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
| US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
| GB9025251D0 (en) * | 1990-11-20 | 1991-01-02 | Solomon Montague C | Nifedipine dosage forms |
| BR9903490A (pt) * | 1998-12-15 | 2000-09-26 | Oscar Gold | Processo para a preparação de composições farmacêuticas de liberação programada contendo nimodipine, que permitem a liberação gradual e a manuntenção da ação terapeutica |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| DE04801160T1 (de) * | 2003-12-01 | 2007-08-09 | Lifecycle Pharma A/S | Pharmazeutische zusammensetzungen mit lercanidipin |
| ZA200605290B (en) * | 2003-12-01 | 2007-10-31 | Lifecycle Pharma As | Pharmaceutical compositions comprising lercanidipine |
| MX2009002235A (es) * | 2006-08-30 | 2009-03-13 | Jagotec Ag | Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina. |
| EP2101771A2 (en) * | 2006-12-06 | 2009-09-23 | Torrent Pharmaceuticals Ltd | Stable lercanidipine formulation |
| WO2009012791A1 (en) * | 2007-07-23 | 2009-01-29 | Pharmathen S.A. | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
-
2007
- 2007-07-23 WO PCT/EP2007/006517 patent/WO2009012791A1/en not_active Ceased
- 2007-07-23 KR KR1020107001425A patent/KR101632079B1/ko active Active
- 2007-07-23 CA CA2691752A patent/CA2691752C/en active Active
- 2007-07-23 CN CN200780100025A patent/CN101784260A/zh active Pending
- 2007-07-23 NZ NZ582648A patent/NZ582648A/en unknown
- 2007-07-23 JP JP2010517273A patent/JP5769963B2/ja not_active Expired - Fee Related
- 2007-07-23 EA EA201070160A patent/EA021645B1/ru not_active IP Right Cessation
- 2007-07-23 ES ES07786262.1T patent/ES2622495T3/es active Active
- 2007-07-23 BR BRPI0721883-4A2A patent/BRPI0721883A2/pt not_active IP Right Cessation
- 2007-07-23 AU AU2007356942A patent/AU2007356942B2/en active Active
- 2007-07-23 UA UAA201001781A patent/UA97161C2/ru unknown
- 2007-07-23 EP EP07786262.1A patent/EP2180883B1/en active Active
- 2007-07-23 MX MX2010000856A patent/MX2010000856A/es active IP Right Grant
-
2008
- 2008-07-23 AU AU2008280106A patent/AU2008280106B9/en not_active Ceased
- 2008-07-23 NZ NZ582690A patent/NZ582690A/en not_active IP Right Cessation
- 2008-07-23 JP JP2010517393A patent/JP2010534220A/ja active Pending
- 2008-07-23 CN CN201410243247.6A patent/CN103976968A/zh active Pending
- 2008-07-23 KR KR1020107002430A patent/KR101512404B1/ko not_active Expired - Fee Related
- 2008-07-23 MY MYPI2010000318A patent/MY153857A/en unknown
- 2008-07-23 CA CA2693233A patent/CA2693233A1/en not_active Abandoned
- 2008-07-23 BR BRPI0814666A patent/BRPI0814666A2/pt not_active IP Right Cessation
- 2008-07-23 UA UAA201000447A patent/UA99136C2/ru unknown
- 2008-07-23 CN CN200880100075A patent/CN101801347A/zh active Pending
- 2008-07-23 ES ES08775312.5T patent/ES2537063T3/es active Active
- 2008-07-23 EP EP20080775312 patent/EP2170295B1/en active Active
- 2008-07-23 EA EA201000220A patent/EA019614B1/ru unknown
- 2008-07-23 WO PCT/EP2008/059645 patent/WO2009013306A1/en not_active Ceased
- 2008-07-23 MX MX2010000801A patent/MX2010000801A/es active IP Right Grant
-
2010
- 2010-01-08 TN TNP2010000011A patent/TN2010000011A1/fr unknown
- 2010-01-13 TN TNP2010000022A patent/TN2010000022A1/fr unknown
- 2010-01-20 CO CO10005281A patent/CO6290639A2/es not_active Application Discontinuation
- 2010-01-26 ZA ZA2010/00586A patent/ZA201000586B/en unknown
- 2010-02-17 MA MA32628A patent/MA31684B1/fr unknown
- 2010-02-18 ZA ZA2010/01176A patent/ZA201001176B/en unknown
- 2010-02-19 CR CR11285A patent/CR11285A/es unknown
- 2010-02-23 EC EC2010009984A patent/ECSP109984A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534220A5 (OSRAM) | ||
| EP2068839B1 (en) | Pharmaceutical compositions comprising nilotinib or its salt | |
| JP6875407B2 (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| JP2010511663A5 (OSRAM) | ||
| JP2014532638A5 (OSRAM) | ||
| CN1358090A (zh) | 左旋多巴/卡比多巴/恩他卡朋药物制剂 | |
| JP2007091758A5 (OSRAM) | ||
| JP2007302683A5 (OSRAM) | ||
| JP2017525712A5 (OSRAM) | ||
| JP2009235073A5 (OSRAM) | ||
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| WO2012164578A1 (en) | Compositions and methods for preparing immediate release formulations of nilotinib | |
| JP2015533129A (ja) | チカグレロルを含む固形経口医薬製剤 | |
| JP2013518860A (ja) | Ｎ−（２−クロロ−６−メチルフェニル）−２−［［６−［４−（２−ヒドロキシエチル）−１−ピペラジニル］−２−メチル−４−ピリミジニル］アミノ］−５−チアゾールカルボサキミドを含む医薬組成物 | |
| RU2011112362A (ru) | Твердые препаративные формы оспемифена | |
| WO2015030854A1 (en) | Solid dispersion formulation of an antiviral compound | |
| JP2009502807A5 (OSRAM) | ||
| CA2623018A1 (en) | Pharmaceutical compositions of telmisartan | |
| JP5854371B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤 | |
| JP6302802B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 | |
| CA2612481A1 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
| JP2019516765A5 (OSRAM) | ||
| JP2013544272A5 (OSRAM) | ||
| ES2349317T3 (es) | Formulaciones farmacéuticas que contienen irbesartán. | |
| JP2009501214A (ja) | クロピドグレルビスルファートを含有する薬学的組成物 |